Journal: Pathology Oncology Research

Article Title: Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

doi: 10.1007/s12253-019-00734-w

Figure Lengend Snippet: Overexpression of serotonin and dopamine receptors in different tumour types determined with functional genomic mRNA analysis

Article Snippet: Primary antibodies used were mouse monoclonal 5-HTR1B 1:100 (clone 499,325; MAB5858, R&D systems, Abingdon, United Kingdom), mouse monoclonal 5-HTR2B 1:1000 (clone H-11; sc-376,834, Santa Cruz Biotechnology, Bio-Connect, Huissen, The Netherlands), mouse monoclonal DRD2 1:100 (clone B-10, sc-5303, Santa Cruz Biotechnology), rat monoclonal DRD1 1:75 (clone 1–1-F11 s.E6; D2944, Sigma Aldrich, Zwijndrecht, The Netherlands), and mouse monoclonal CD31 1:50 (clone JC70A; IR610, DAKO, Glostrup, Denmark).

Techniques: Over Expression, Functional Assay

Journal: Pathology Oncology Research

Article Title: Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

doi: 10.1007/s12253-019-00734-w

Figure Lengend Snippet: a Serotonin receptor 1B (5-HTR1B), b serotonin receptor 2B (5-HTR2B), c dopamine receptor D1 (DRD1), d and dopamine receptor D2 (DRD2) expression on tumour cells of colon cancer (CC) ( n = 12), ovarian cancer (OC) ( n = 12), breast cancer (BC) ( n = 12), renal cell carcinoma (RCC) ( n = 14), pancreatic cancer (PC) ( n = 12), melanoma (M) ( n = 36), pheochromocytoma (PCC) ( n = 63) and gastrointestinal stromal tumours (GIST) ( n = 76) as analysed with immunohistochemistry. Immunoreactive score (IRS) was used to classify receptor expression on tumour cells in three categories: negative (in white), low (in light grey) or high (in dark grey)

Article Snippet: Primary antibodies used were mouse monoclonal 5-HTR1B 1:100 (clone 499,325; MAB5858, R&D systems, Abingdon, United Kingdom), mouse monoclonal 5-HTR2B 1:1000 (clone H-11; sc-376,834, Santa Cruz Biotechnology, Bio-Connect, Huissen, The Netherlands), mouse monoclonal DRD2 1:100 (clone B-10, sc-5303, Santa Cruz Biotechnology), rat monoclonal DRD1 1:75 (clone 1–1-F11 s.E6; D2944, Sigma Aldrich, Zwijndrecht, The Netherlands), and mouse monoclonal CD31 1:50 (clone JC70A; IR610, DAKO, Glostrup, Denmark).

Techniques: Expressing, Immunohistochemistry

Journal: Pathology Oncology Research

Article Title: Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

doi: 10.1007/s12253-019-00734-w

Figure Lengend Snippet: a Serotonin receptor 1B (5-HTR1B), b serotonin receptor 2B (5-HTR2B), c dopamine receptor D1 (DRD1), d and dopamine receptor D2 (DRD2) expression on endothelial cells of colon cancer (CC) ( n = 12), ovarian cancer (OC) ( n = 12), breast cancer (BC) ( n = 12), renal cell carcinoma (RCC) ( n = 14), and pancreatic cancer (PC) ( n = 12) as analysed with immunohistochemistry. Receptor expression was classified by staining intensity. Receptor expression was considered negative if intensity was 0 (white), low if intensity was 1 (in light grey), and high if intensity was 2 or 3 (in dark grey)

Article Snippet: Primary antibodies used were mouse monoclonal 5-HTR1B 1:100 (clone 499,325; MAB5858, R&D systems, Abingdon, United Kingdom), mouse monoclonal 5-HTR2B 1:1000 (clone H-11; sc-376,834, Santa Cruz Biotechnology, Bio-Connect, Huissen, The Netherlands), mouse monoclonal DRD2 1:100 (clone B-10, sc-5303, Santa Cruz Biotechnology), rat monoclonal DRD1 1:75 (clone 1–1-F11 s.E6; D2944, Sigma Aldrich, Zwijndrecht, The Netherlands), and mouse monoclonal CD31 1:50 (clone JC70A; IR610, DAKO, Glostrup, Denmark).

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Pathology Oncology Research

Article Title: Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

doi: 10.1007/s12253-019-00734-w

Figure Lengend Snippet: a Representative images of low and high expression of serotonin receptor 1B (5-HTR1B), serotonin receptor 2B (5-HTR2B), dopamine receptor D1 (DRD1), and dopamine receptor D2 (DRD2) by tumour cells in ovarian cancer (10x magnification). b Representative images of negative and positive (low or high) expression of serotonin receptor 1B (5-HTR1B), serotonin receptor 2B (5-HTR2B), dopamine receptor D1 (DRD1), and dopamine receptor D2 (DRD2) on blood vessels in ovarian cancer (40x magnification). Arrowheads indicate blood vessels that express the receptor of interest

Article Snippet: Primary antibodies used were mouse monoclonal 5-HTR1B 1:100 (clone 499,325; MAB5858, R&D systems, Abingdon, United Kingdom), mouse monoclonal 5-HTR2B 1:1000 (clone H-11; sc-376,834, Santa Cruz Biotechnology, Bio-Connect, Huissen, The Netherlands), mouse monoclonal DRD2 1:100 (clone B-10, sc-5303, Santa Cruz Biotechnology), rat monoclonal DRD1 1:75 (clone 1–1-F11 s.E6; D2944, Sigma Aldrich, Zwijndrecht, The Netherlands), and mouse monoclonal CD31 1:50 (clone JC70A; IR610, DAKO, Glostrup, Denmark).

Techniques: Expressing

Journal: Cell reports

Article Title: Genetic and Functional Dissection of the Role of Individual 5-HT 2 Receptors as Entry Receptors for JC Polyomavirus

doi: 10.1016/j.celrep.2019.04.067

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-5-HT 2B R was obtained from Novus Biologicals cat# NLS1111 and recognizes the second extracellular loop.

Techniques: Generated, Virus, Recombinant, Mutagenesis, Luciferase, Control, Plasmid Preparation, Software, CRISPR

Journal: International Journal of Molecular Sciences

Article Title: Improvement Effects of Myelophil on Symptoms of Chronic Fatigue Syndrome in a Reserpine-Induced Mouse Model

doi: 10.3390/ijms221910199

Figure Lengend Snippet: Changes in 5-HT1A receptor (5-HT1AR) expression in each brain region following myelophil (MYP) treatment. The number of 5-HT1AR-positive cells was significantly changed by 100 mg/kg MYP treatment in the motor cortex area 2 (M2), infralimbic cortex (IL), striatum (ST), cornu ammonis area 1 of hippocampus (CA1), lateral part of the dorsal raphe nucleus (DRL), dorsal part of the dorsal raphe nucleus (DRD), ventral part of the dorsal raphe nucleus (DRV), and interfascicular part of the dorsal raphe nucleus (DRI) regions. CON: control ( n = 5), CON + MYP100: 100 mg/kg MYP treatment ( n = 5), RES: 2 mg/kg of reserpine treatment ( n = 5), RES + MYP100: 2 mg/kg of reserpine followed by 100 mg/kg of MYP treatment ( n = 5). Data are expressed as means ± SEM. One-way ANOVA test with Tukey post hoc tests was executed. ** p < 0.01, *** p < 0.001, vs. CON; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. RES.

Article Snippet: Endogenous peroxidase in the brain tissue was inactivated by 3% H2O2 for 20 min and then tissues were incubated with 1% bovine serum albumin (BSA, BOVOGEN, Williams Ave, Keilor East VIC, Australia) at room temperature for 1 h. Tissues were incubated with primary antibodies as follows: c-Fos (1:250; Abcam, AB222699, Cambridge, MA, USA), 5-HT1AR (1:100; Novus Biologicals, NBP2-21590, Centennial, CO, USA), 5-HT1BR (1:100; Abcam, AB13896, Cambridge, MA, USA), TGF-β1 (1:100; Abcam, AB215715, Cambridge, MA, USA), and TH (1:100; Abcam, AB112, Cambridge, MA, USA) at 4 °C overnight.

Techniques: Expressing, Control

Journal: International Journal of Molecular Sciences

Article Title: Improvement Effects of Myelophil on Symptoms of Chronic Fatigue Syndrome in a Reserpine-Induced Mouse Model

doi: 10.3390/ijms221910199

Figure Lengend Snippet: Identification of the major brain regions based on the changes in the expression of c-Fos and 5-HT1A/B receptors and TGF-β1 following myelophil (MYP) treatment. Percentage of cells positive for c-Fos ( a ), 5-HT1A receptor (5-HT1AR) ( b ), 5-HT1B receptor (5-HT1BR) ( c ), and TGF-β1 ( d ) in 24 brain regions after MYP treatment in the order of change. The overlap between the brain regions showing more than 15% ( e ) or 20% ( f ) difference in the expression of c-Fos, 5-HT1A/B receptors and TGF-β1 after MYP treatment.

Article Snippet: Endogenous peroxidase in the brain tissue was inactivated by 3% H2O2 for 20 min and then tissues were incubated with 1% bovine serum albumin (BSA, BOVOGEN, Williams Ave, Keilor East VIC, Australia) at room temperature for 1 h. Tissues were incubated with primary antibodies as follows: c-Fos (1:250; Abcam, AB222699, Cambridge, MA, USA), 5-HT1AR (1:100; Novus Biologicals, NBP2-21590, Centennial, CO, USA), 5-HT1BR (1:100; Abcam, AB13896, Cambridge, MA, USA), TGF-β1 (1:100; Abcam, AB215715, Cambridge, MA, USA), and TH (1:100; Abcam, AB112, Cambridge, MA, USA) at 4 °C overnight.

Techniques: Expressing